Current role: Director at Vesmyr Life Sciences Inc.
John has over 35 years of experience in the Life Sciences sector covering Pharma/Biotech, Lab Diagnostics and Medical Devices. He possesses a successful track record of innovative technology commercialization including market assessment, reimbursement, KOL development, product launch and distribution strategies on a global basis. John also has successfully managed full P/L responsibility in lab diagnostics and has executed licensing agreements in the pharma/biotech space.
Prior to co-founding Vesmyr Life Sciences, John was Senior Director of Business Development at Isotechnika Pharma (Aurinia) where his responsibilities included all related BD activities globally in support of licensing lead compounds in development for transplant and autoimmune indications which included identifying and securing strategic license partnerships negotiations, due diligence, market analysis, term sheets and valuations. In this role, John secured Amendments to the Atrium License agreement to re-acquire ophthalmic indications, secured the Global Distribution and License Agreement with Lux Biosciences for Ophthalmic Indications participated in the Joint Steering Committee, negotiated and secured the Toll Manufacturing Agreement for API with Lonza Switzerland, negotiated and secured a contract for formulation/encapsulation with Catalent Pharma Solutions. He additionally secured a license agreement with 3SBIO for voclosporin in China.